258 related articles for article (PubMed ID: 27716152)
1. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
2. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial.
Armenian SH; Hudson MM; Lindenfeld L; Chen S; Chow EJ; Colan S; Collier W; Su X; Marcus E; Echevarria M; Iukuridze A; Robison LL; Wong FL; Chen MH; Bhatia S
Lancet Oncol; 2024 Feb; 25(2):235-245. PubMed ID: 38215764
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
Hori M; Nagai R; Izumi T; Matsuzaki M
Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
Park K; Park TH
Trials; 2016 Nov; 17(1):530. PubMed ID: 27809882
[TBL] [Abstract][Full Text] [Related]
5. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.
Palazzuoli A; Bruni F; Puccetti L; Pastorelli M; Angori P; Pasqui AL; Auteri A
Eur J Heart Fail; 2002 Dec; 4(6):765-70. PubMed ID: 12453548
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
8. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
Lindenfeld J; Robertson AD; Lowes BD; Bristow MR;
J Am Coll Cardiol; 2001 Dec; 38(7):1950-6. PubMed ID: 11738299
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol.
Kaya MG; Sarli B; Akpek M; Kaya EG; Yarlioglues M; Topsakal R; Lam YY
Cardiol J; 2014; 21(4):434-41. PubMed ID: 24142686
[TBL] [Abstract][Full Text] [Related]
10. The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design.
Shaddy RE; Curtin EL; Sower B; Tani LY; Burr J; LaSalle B; Boucek MM; Mahony L; Hsu DT; Pahl E; Burch GH; Schlencker-Herceg R
Am Heart J; 2002 Sep; 144(3):383-9. PubMed ID: 12228773
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
12. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol.
Capomolla S; Febo O; Gnemmi M; Riccardi G; Opasich C; Caporotondi A; Mortara A; Pinna GD; Cobelli F
Am Heart J; 2000 Apr; 139(4):596-608. PubMed ID: 10740140
[TBL] [Abstract][Full Text] [Related]
13. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial).
Carrasco R; Ramirez MC; Nes K; Schuster A; Aguayo R; Morales M; Ramos C; Hasson D; Sotomayor CG; Henriquez P; Cortés I; Erazo M; Salas C; Gormaz JG
Trials; 2020 Feb; 21(1):137. PubMed ID: 32019575
[TBL] [Abstract][Full Text] [Related]
14. [The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy].
Metra M; Nodari S; Garbellini M; Boldi E; Rosselli F; Milan E; Giubbini R; Dei Cas L
Cardiologia; 1997 May; 42(5):503-12. PubMed ID: 9289367
[TBL] [Abstract][Full Text] [Related]
15. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
16. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group.
Lancet; 1997 Feb; 349(9049):375-80. PubMed ID: 9033462
[TBL] [Abstract][Full Text] [Related]
17. Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.
Ohtani K; Fujino T; Ide T; Funakoshi K; Sakamoto I; Hiasa KI; Higo T; Kamezaki K; Akashi K; Tsutsui H
Clin Res Cardiol; 2019 Jun; 108(6):600-611. PubMed ID: 30367208
[TBL] [Abstract][Full Text] [Related]
18. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management.
Nabeta T; Inomata T; Iida Y; Ikeda Y; Iwamoto-Ishida M; Ishii S; Naruke T; Mizutani T; Shinagawa H; Koitabashi T; Takeuchi I; Ako J
Heart Vessels; 2016 Jul; 31(7):1109-16. PubMed ID: 26253941
[TBL] [Abstract][Full Text] [Related]
20. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
Bergström A; Andersson B; Edner M; Nylander E; Persson H; Dahlström U
Eur J Heart Fail; 2004 Jun; 6(4):453-61. PubMed ID: 15182771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
